Protein biomarkers of inflammatory activity in multiple sclerosis
AssigneesOklahoma Medical Research Foundation, The Board of Regents of the University of Oklahoma
InventorsRobert C. AXTELL, Saurabh GAWDE
Life of this patent
Estimating the term…
Abstract
The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.
Claims27
A method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising:
- (a) determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS;
- (b) diagnosing the subject in (a) as undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject;
- and
- (c) administering a therapeutically effective amount of a treatment for RRMS to the subject diagnosed in (b).
A method for determining whether a subject with relapsing-remitting multiple sclerosis (RRMS) with an elevated level of an NfL biomarker is having or will have a relapse, comprising:
- (a) determining in a biological sample from the subject a level of expression for one or more biomarkers selected from uPA, hK8, hK11, or DSG3 when compared to the same sample from a subject or a population of subjects that do not have RRMS, wherein the combination of the NfL biomarker and the one or more biomarker selected from uPA, hK8, hK11, or DSG3 has a higher sensitivity and selectivity that using NfL biomarker alone;
- (b) diagnosing the subject in (a) as undergoing relapse if the expression level of the uPA, hK8, hK11 or DSG3 has decreased, and
- (c) administering a therapeutically effective amount of a treatment for RRMS to the subject diagnosed in (b).
A method for detecting relapse in a subject with relapsing-remitting multiple sclerosis (RRMS), comprising:
- (a) determining a level of expression for two or more biomarkers selected from uPA, hK8, hK11, or DSG3 in a biological sample of the subject when compared to the same sample from a subject or a population of subjects that do not have RRMS and wherein one of the biomarkers is not an NfL biomarker, wherein the two or more biomarker selected from uPA, hK8, hK11, or DSG3 has a higher sensitivity and selectivity that the Nfl biomarker alone;
- (b) diagnosing the subject in (a) as undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject, and
- (c) administering a therapeutically effective amount of a treatment for RRMS to the subject diagnosed in (b).
Dependencies are inferred from the claim text.